Therapeutic drug monitoring survey of anti-MRSA agents in Japan

Masahiro Kobayashi, Yoshio Takesue, Yusuke Tanigawara, Hiroshige Mikamo, Toshimi Kimura, Sumio Hirata, Tadashi Shiraishi, Toshiyuki Sakaeda, Shunji Takakura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume58
Issue number2
Publication statusPublished - 2010 Mar
Externally publishedYes

Fingerprint

Drug Monitoring
Methicillin-Resistant Staphylococcus aureus
Japan
Teicoplanin
Vancomycin
Pharmacists
Health Insurance
Referral and Consultation
Surveys and Questionnaires
Costs and Cost Analysis
Drug Therapy
Serum
habekacin

Keywords

  • Arbekacin
  • Questionnaire
  • Teicoplanin
  • Therapeutic drug monitoring
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kobayashi, M., Takesue, Y., Tanigawara, Y., Mikamo, H., Kimura, T., Hirata, S., ... Takakura, S. (2010). Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Japanese Journal of Chemotherapy, 58(2), 119-124.

Therapeutic drug monitoring survey of anti-MRSA agents in Japan. / Kobayashi, Masahiro; Takesue, Yoshio; Tanigawara, Yusuke; Mikamo, Hiroshige; Kimura, Toshimi; Hirata, Sumio; Shiraishi, Tadashi; Sakaeda, Toshiyuki; Takakura, Shunji.

In: Japanese Journal of Chemotherapy, Vol. 58, No. 2, 03.2010, p. 119-124.

Research output: Contribution to journalArticle

Kobayashi, M, Takesue, Y, Tanigawara, Y, Mikamo, H, Kimura, T, Hirata, S, Shiraishi, T, Sakaeda, T & Takakura, S 2010, 'Therapeutic drug monitoring survey of anti-MRSA agents in Japan', Japanese Journal of Chemotherapy, vol. 58, no. 2, pp. 119-124.
Kobayashi M, Takesue Y, Tanigawara Y, Mikamo H, Kimura T, Hirata S et al. Therapeutic drug monitoring survey of anti-MRSA agents in Japan. Japanese Journal of Chemotherapy. 2010 Mar;58(2):119-124.
Kobayashi, Masahiro ; Takesue, Yoshio ; Tanigawara, Yusuke ; Mikamo, Hiroshige ; Kimura, Toshimi ; Hirata, Sumio ; Shiraishi, Tadashi ; Sakaeda, Toshiyuki ; Takakura, Shunji. / Therapeutic drug monitoring survey of anti-MRSA agents in Japan. In: Japanese Journal of Chemotherapy. 2010 ; Vol. 58, No. 2. pp. 119-124.
@article{0d0a66066c734aaa80fec06672b2ab99,
title = "Therapeutic drug monitoring survey of anti-MRSA agents in Japan",
abstract = "We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6{\%}) institutions. In over 80{\%} of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.",
keywords = "Arbekacin, Questionnaire, Teicoplanin, Therapeutic drug monitoring, Vancomycin",
author = "Masahiro Kobayashi and Yoshio Takesue and Yusuke Tanigawara and Hiroshige Mikamo and Toshimi Kimura and Sumio Hirata and Tadashi Shiraishi and Toshiyuki Sakaeda and Shunji Takakura",
year = "2010",
month = "3",
language = "English",
volume = "58",
pages = "119--124",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "2",

}

TY - JOUR

T1 - Therapeutic drug monitoring survey of anti-MRSA agents in Japan

AU - Kobayashi, Masahiro

AU - Takesue, Yoshio

AU - Tanigawara, Yusuke

AU - Mikamo, Hiroshige

AU - Kimura, Toshimi

AU - Hirata, Sumio

AU - Shiraishi, Tadashi

AU - Sakaeda, Toshiyuki

AU - Takakura, Shunji

PY - 2010/3

Y1 - 2010/3

N2 - We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.

AB - We distributed questionnaires to determine therapeutic drug monitoring(TDM) status for anti-MRSA agents vancomycin(VCM), teicoplanin(TEIC), and arbekacin(ABK) in 563 Japanese hospitals having pharmacists enrolled in the Japanese Society of Chemotherapy. Responses were collected from 302 (53.6%) institutions. In over 80% of facilities, pharmacists provide clinical consultation on anti-MRSA agents based on TDM. General recommendations for monitoring serum drugs concentrations are as follows: (1) VCM, trough concentration on day 3 targeting >10 μg/mL; (2) TEIC, on day 4 targeting >15 μg/mL; and (3) ABK, on day 3 targeting <2μg/mL and peak >9 μg/mL. Answers for main questions such as sample timing, sampling points, and targeted concentrations, were roughly equivalent to our recommendations. Standardizing TDM involves problems including large inter institutional differences in ABK TDM and no claim of rights to cost monitoring more than twice a month under the current government-run health insurance system.

KW - Arbekacin

KW - Questionnaire

KW - Teicoplanin

KW - Therapeutic drug monitoring

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=77950801821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950801821&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77950801821

VL - 58

SP - 119

EP - 124

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 2

ER -